The approvals, announced by the companies yesterday, cover adults 65 and older plus younger people with chronic conditions that raise their risk of severe disease. Pfizer has already begun shipping doses to pharmacies. Most insurers have committed to covering the shots at no cost to patients through at least the end of 2027.
Three Vaccines, Three Approval Footprints
Each manufacturer received a slightly different clearance. Pfizer’s mRNA vaccine, Comirnaty XFG, is approved for adults 65 and older and for people ages 5 to 64 with an underlying condition. The company said doses should reach pharmacies soon.
Moderna secured approval for two products. Its mRNA vaccine Spikevax is cleared for people 65 and older and those 6 months to 64 years old with an underlying condition. A newer lower-dose mRNA vaccine, mNEXSPIKE, is approved for adults 65 and older and people 12 to 64 with an underlying condition.
Sanofi’s Nuvaxovid, a protein-based vaccine originally licensed by Novavax that does not rely on mRNA technology, is approved for adults 65 and older and people 12 to 64 at high risk for severe COVID-19. The non-mRNA option may appeal to patients who have avoided mRNA shots.
Who Qualifies Under The Risk-Based Approval
The CDC lists a broad set of conditions that can increase the risk of severe COVID-19, including asthma, cancer, chronic lung or kidney disease, mental illness, obesity, pregnancy, and smoking. The agency’s current map shows cases growing or likely growing in 48 states, underscoring why regulators prioritized high-risk groups for the updated formulation.
Healthy adults under 65 without qualifying conditions are not covered under the current approvals, a narrower scope than prior seasons that broadly recommended the shots for all ages. Patients unsure of their eligibility should check with a pharmacist or physician before booking.
Cost And Access For Patients
AHIP, the trade group representing most health insurers, said its members will cover the full cost of vaccines recommended by a CDC advisory committee at least through the end of 2027. CVS, one of the largest U.S. drugstore chains, is already advertising free COVID-19 vaccines with most insurance, though it notes appointments may be unavailable in some states.
Patients without insurance, or whose plans fall outside the AHIP commitment, may face out-of-pocket charges. Public health experts have warned that cost barriers could slow uptake among the very high-risk groups the approvals are designed to protect.
What Happens Next
Watch pharmacy inventory over the coming weeks as Pfizer, Moderna, and Sanofi ramp distribution. CVS and rival chains are expected to expand appointment availability as shipments arrive. The CDC’s advisory committee schedule and any broader age recommendations will shape whether eligibility widens later this season. With cases climbing in nearly every state, uptake among adults 65 and older and chronically ill younger patients will determine whether the updated COVID vaccines blunt a fall wave.
— Aisha Mensah, health desk, AXO News